Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 15/20 | 0.84 |
| ▸ | ACP1 | P24666 | 3/20 | 0.61 |
| ▸ | PDE5A | O76074 | 2/20 | 0.58 |
| ▸ | LATS1 | O95835 | 2/20 | 0.56 |
| ▸ | LATS2 | Q9NRM7 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3459452 | 1.00 | GBA1 (0.84) | GBA1ACP1PDE5ALATS1LATS2 | |
| SCHEMBL18353889 | 0.88 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18354429 | 0.88 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18353972 | 0.88 | GBA1 (1.00) | GBA1 | |
| SCHEMBL18354432 | 0.84 | GBA1 (1.00) | GBA1ACP1PDE5A | |
| SCHEMBL3460201 | 0.83 | ACP1 (0.84) | GBA1ACP1PDE5ALATS1LATS2 | |
| SCHEMBL1083972 | 0.82 | ACP1 (0.85) | GBA1ACP1PDE5ALATS1LATS2 | |
| SCHEMBL3459467 | 0.81 | GBA1 (0.78) | GBA1ACP1PDE5ALATS1LATS2 | |
| SCHEMBL22201548 | 0.80 | ACP1 (0.73) | GBA1ACP1PDE5ALATS1LATS2 | |
| SCHEMBL3459522 | 0.80 | CYP1A2 (0.71) | GBA1ACP1PDE5ALATS1LATS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | claimed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | claimed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-7763627-B2 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| EP-1610774-A4 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS INC (US) | 2008-07-16 | — | — | EP | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| US-20070161651-A1 | Tie-2 modulators and methods of use | EXELIXIS, INC. (US) | 2007-07-12 | — | — | US | disclosed |
| EP-1610774-A2 | TIE-2 MODULATORS AND METHODS OF USE | Exelixis, Inc. (US) | 2006-01-04 | — | — | EP | disclosed |
| WO-2004092196-A2 | TIE-2 MODULATORS AND METHODS OF USE | EXELIXIS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070161651-A1 | Tie-2 modulators and methods of use | TIE1, TEK, KDR | GBA1 4763/4885ACP1 1276/4885PDE5A 1963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.